Skip to main content Back to Top


Vinblastine Sulfate Injection

Products Affected - Description

    • Vinblastine Sulfate, Fresenius Kabi, 10 mg/mL, 10 mL multiple dose vial, 1 count, NDC 63323-0278-10

Reason for the Shortage

    • Fresenius Kabi has vinblastine on shortage due to a short-term manufacturing delay. They are the sole suppliers of vinblastine.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Fresenius Kabi has vinblastine available for direct and drop ship orders. The company estimates the next release date of mid-January 2020.

Alternative Agents & Management

    • Vinblastine is labeled as a multiple dose vial. To avoid waste during this shortage, consider either using as a multiple dose vial or rounding doses to the vial size when appropriate.
    • Review available stock prior to initiating new patients on therapy.


Updated November 25, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 15, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins